Analysts are saying that Eli Lilly & Co. could hit $2,740 by 2030. Bullish on LLY? Invest in Eli Lilly & Co. on SoFi with no commissions. If it’s your first time signing up for SoFi, you’ll receive up to $1,000 in stock when you first fund your account. Plus, get a 1% bonus if you transfer your investments and keep them there until December 31, 2025.
Eli Lilly & Co. (LLY) continues to deliver impressive revenue growth on the back of key weight-loss and diabetes treatments. Raised guidance may lead to upside for the stock, which has suffered a 19% drop over the last year. Some investors believe LLY is due for a rebound, but others see the downward trend sticking around.
In this article, we’ll look at Eli Lilly’s latest share price, Wall Street sentiment, multiyear price forecasts, and the key factors that are playing a critical role in the company’s path going forward.
Current Stock Overview
Market Cap: $670 billion
Trailing P/E Ratio: 48.90
Forward P/E Ratio: 24.81
1-Year Return: -19%
2025 YTD: -3%
Eli Lilly shares have lost 19% of their value over the last year and are down by 3% year-to-date. The stock trades at approximately $752 per share as of September 2025. A high P/E ratio compared to peers like Novo Nordisk (NVO), Merck & Co. Inc. (MRK), and Johnson & Johnson (JNJ) suggests LLY has more room to fall.
Eli Lilly’s growth largely comes from its successful weight loss and diabetes medications, respectively Zepbound and Mounjaro. Those two products helped the company deliver 38% year-over-year revenue growth in the second quarter and 92% year-over-year earnings per share (EPS) growth. Eli Lilly proceeded to raise its full-year guidance thanks to the strong results, indicating more potential upside.
Positive results in experimental drugs orforglipron for obesity and Jaypirca H2H for certain cancers, along with Mounjaro gaining more market share, are some of the catalysts in the pipeline. The company also completed the acquisitions of SiteOne Therapeutics, Inc. and Verve Therapeutics, Inc., which could lead to higher financial growth rates.
However, competition could put pressure on those growth rates down the road. Novo Nordisk’s Ozempic weight loss medication could limit growth opportunities for fellow weight-loss injectable, Zepbound, by stealing some of its market share.
LLY has a consensus Buy rating from 28 analysts, according to Benzinga. The average price target is $937.81 per share, which suggests a meaningful 24.7% gain from current levels. The highest price target is $1,190, and the lowest is $610. The three most recent ratings suggest a near-term average target of $860, suggesting a 14.32% upside.
Quick Snapshot Table of Predictions
| Year | Lowest Prediction ($) | Average Prediction ($) | Maximum Prediction ($) |
| 2025 | 745.02 | 767.73 | 789.48 |
| 2026 | 999.57 | 1,030.81 | 1,099.88 |
| 2027 | 1,800.43 | 1,885.31 | 1,982.94 |
| 2028 | 2,939.25 | 3,059.61 | 3,187.63 |
| 2029 | 2,429.57 | 2,483.94 | 2,512.90 |
| 2030 | 2,668.35 | 2,694.09 | 2,740.05 |
The forecast range in this table is based on algorithmic projections provided by CoinCodex. These models use historical price trends, volatility patterns and moving averages to estimate future stock prices over multiple time horizons.
Bull & Bear Case
LLY stock has plenty of bullish analysts, but there are a few concerns to keep in mind before buying the stock. These are some of the pros and cons to keep in mind.
Bull Case
- Zepbound and Mounjaro continue to gain market share
- Rising revenue and profits can set the stage for more gains
- Positive results from products in the pipeline and recent acquisitions can fuel new revenue opportunities
Bear Case
- LLY stock has a rich P/E ratio compared to its peers, suggesting further downside if the company can’t maintain exceptional financial growth rates
- Zepbound faces a strong competitor in Ozempic
- Experimental drugs don’t get the type of reception Eli Lilly expects
Stock Price Prediction for 2025
Forecast Range: $745.02 – $789.48
CoinCodex forecasts Eli Lilly reaching an average estimated value of $767.73 per share this year, implying a slight gain from the current price. Rising revenue growth and upbeat guidance may be enough to help the stock reach that price point.
Stock Price Prediction for 2026
Forecast Range: $999.57 – $1,099.88
CoinCodex sees Eli Lilly reaching an average estimated value of $1,030.81 per share, suggesting a 37% gain from current levels. The company’s pipeline, acquisitions, and successful drugs may push the stock price higher.
Stock Price Prediction for 2030
Forecast Range: $2,668.35 – $2,740.05
CoinCodex projects an average price target of $2,694.09 per share, which suggests a substantial upside from current levels and a 29.07% CAGR over the next five years. Innovative drugs and existing drugs gaining more market share can help LLY outperform its competitors and justify a high valuation.
However, any revenue growth deceleration, mishaps with drugs, and rising competition can derail this forecast.
Investment Considerations
Eli Lilly’s weight loss and diabetes medications have fueled impressive revenue growth that resulted in optimistic guidance for the rest of the year. Novo Nordisk’s Ozempic remains a strong competitor that could impact Eli Lilly’s ability to gain market share in the weight-loss medication industry in the future, but earnings are looking solid right now. Experimental medications are going through the pipeline and could present additional revenue opportunities once they are approved.
However, Eli Lilly trades at a rich valuation compared to its peers, which can lead to a correction if revenue growth slows down.
Key risks: Competition, valuation pressure, product pipeline and acquisition don’t pan out, regulatory problems for future products, and any slowdowns for Eli Lilly’s top-performing drugs
Eli Lilly caters to growth investors who want exposure to the healthcare sector. The company is growing at a fast rate, but investors must not be afraid of a lofty valuation if they want to buy LLY shares.
Frequently Asked Questions
A
LLY stock may be a good long-term investment. It’s growing at a fast rate, and analysts are bullish about the stock’s long-term prospects.
A
CoinCodex projects an average price target of $2,694.09 per share by 2030, which suggests a substantial upside from current levels.
A
No. LLY stock does not pay a dividend. The company regularly reinvests its profits back into the business.
